A Large-Scale Proteomics Resource of Circulating Extracellular Vesicles for Biomarker

Discovery in Pancreatic Cancer

Bruno Bockorny[1,2*], Lakshmi Muthuswamy[3*], Ling Huang[4*], Marco Hadisurya[5], Christine Maria Lim[6], Leo L. Tsai[2,7], Ritu R. Gill[2,7], Jesse L. Wei[2,7], Andrea J. Bullock[1,2], Joseph E. Grossman[8], Robert J. Besaw[1], Supraja Narasimhan[9], W. Andy Tao[5], Sofia Perea[1], Mandeep S. Sawhney[2,10], Steven D. Freedman[2,10], Manuel Hidalgo[11,12*], Anton Iliuk[13*†], Senthil K. Muthuswamy[14*†]

Affiliations:
1. Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
2. Harvard Medical School, Boston, MA, USA
3. Blueprint Medicines, Cambridge, MA, USA
4. Henry Ford Cancer Institute, Detroit, MI, USA
5. Department of Biochemistry, Purdue University, West Lafayette, IN, USA
6. Nanyang Technological University, Singapore
7. Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA
8. Agenus Inc, Lexington, MA, USA
9. Deciphera Pharmaceuticals, Waltham, MA, USA
10. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA
11. Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY, USA
12. New York-Presbyterian Hospital, New York, NY, USA
13. Tymora Analytical Operations, West Lafayette, IN, USA
14. National Cancer Institute, NIH, Bethesda, MD, USA

Running Title: Large Scale EV Proteomics Resource to Discover PDAC Biomarkers

Keywords: Proteomics, exosomes, extracellular vesicles, chronic pancreatitis, pancreatic cancer

Correspondence:

Senthil K. Muthuswamy PhD

Laboratory of Cancer Biology and Genetics

LCBG, Bldg. 37, Rm4068, 37 Convent Dr. Bethesda, MD 20892 |Ph:240-858-7734

Senthil.muthuswamy@nih.gov

Anton Iliuk PhD

1201 Cumberland Ave, Suite 209, West Lafayette, IN 47906

anton.iliuk@tymora-analytical.com

* Equal contribution   † Corresponding authors

ABSTRACT

Pancreatic cancer has the worst prognosis of all common tumors. Earlier cancer diagnosis could increase survival rates and better assessment of metastatic disease could improve patient care. As such, there is an urgent need to develop biomarkers to diagnose this deadly malignancy earlier. Analyzing circulating extracellular vesicles (cEVs) using 'liquid biopsies' offers an attractive approach to diagnose and monitor disease status. However, it is important to differentiate EV-associated proteins enriched in patients with pancreatic ductal adenocarcinoma (PDAC) from those with benign pancreatic diseases such as chronic pancreatitis and intraductal papillary mucinous neoplasm (IPMN). To meet this need, we combined the novel EVtrap method for highly efficient isolation of EVs from plasma and conducted proteomics analysis of samples from 124 individuals, including patients with PDAC, benign pancreatic diseases and controls. On average, 912 EV proteins were identified per 100μL of plasma. EVs containing high levels of PDCD6IP, SERPINA12 and RUVBL2 were associated with PDAC compared to the benign diseases in both discovery and validation cohorts. EVs with PSMB4, RUVBL2 and ANKAR were associated with metastasis, and those with CRP, RALB and CD55 correlated with poor clinical prognosis. Finally, we validated a 7-EV protein PDAC signature against a background of benign pancreatic diseases that yielded an 89% prediction accuracy for the diagnosis of PDAC. To our knowledge, our study represents the largest proteomics profiling of circulating EVs ever conducted in pancreatic cancer and provides a valuable open-source atlas to the scientific community with a comprehensive catalogue of

56   novel cEVs that may assist in the development of biomarkers and improve the outcomes of

57   patients with PDAC.

58   **INTRODUCTION**

Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all common tumors, with

a 5-year survival of 12%[1]. With rising incidence, it is expected that PDAC will become the

second leading cause of cancer-related deaths by 2030[2]. A critical factor for this dismal

development is the late diagnosis, with less than 20% of patients presenting with a potentially

resectable and curable tumor[3-5]. Earlier cancer diagnosis could increase the survival rates by an

estimated 5-fold, and more reliable and real-time assessment of treatment effects in patients

with cancer could improve quality of life and reduce healthcare costs[6,7]. Unfortunately, there

are no credentialed serologic biomarkers with high enough performance to assist in the early

detection of PDAC. The best-established biomarker for PDAC, carbohydrate antigen 19-9 (CA19-

9), is fraught with poor sensitivity and specificity and is only used for monitoring disease on

treatment or after surgical resection[8,9].

Extracellular vesicles (EVs), including exosomes and microvesicles, are nanosized particles

released by most cell types and can be detected in the circulation[10]. EVs play important roles in

the transmission of oncogenic and inflammatory signals[11], communications between cells and

their microenvironment[12]. In addition, exoDNA, exoRNA and protein profiles highly reflect

parental cells, therefore offering an attractive strategy for diagnosing cancers non-invasively by

analyzing EVs in the circulation[11,13]. Previous studies employed EVs to discover biomarkers for

PDAC[13-16], however those discovery proteomics experiments were carried out using cell lines or

tumor tissue, which are not representative of the heterogeneity of human PDAC and are unable

to recapitulate the systemic responses to cancer[14-16]. In addition, the EV biomarkers discovered

in those studies have been compared only against healthy controls[14-16]. It is unclear how they

would perform in subjects with underlying benign diseases of the pancreas, which is highly

desirable from the clinical standpoint as many patients with PDAC have underlying chronic

pancreatitis and cysts.

To meet this need, we conducted a large EV proteomics study from peripheral blood across a

range of patients with pancreatic cancer, benign pancreatic diseases such as chronic

pancreatitis and intraductal papillary mucinous neoplasm (IPMN), and healthy controls.

Circulating EV (cEV) proteins detected included those involved in metabolism and immune

regulation, in addition to proteins involved in protein binding, exocytosis, endocytosis and

regulation of cellular protein localization that have been identified in previous studies[17,18]. Our

study represents the largest EV proteomics profiling dataset of pancreatic cancer, therefore

providing a resource to the research community to further the understanding of EV roles in

pancreatic cancer biology and biomarker discovery. To demonstrate the utility of this dataset,

we identified multiple candidate biomarkers for cancer diagnosis and validated several in an

independent cohort of patients with pancreatic cancer. In addition, we identified a set of cEV

proteins associated with metastasis and prognosis which could provide a valuable resource for

future biomarker studies as well as understanding of systemic changes during pancreatic tumor

progression.

RESULTS

Proteomics Characterization of Circulating EVs

In this study, we sought to identify proteins in extracellular vesicles in the blood that may be used as biomarkers for the diagnosis and prognosis of pancreatic cancer. With the approval of our institutional review board, we enrolled a total of 124 patients to the discovery cohort of this biomarker study (**Methods and Supplementary Table 1**). Subjects in the pancreatic cancer group (N=93) had a mean age of 66.5 years (range, 37-91), and 48.4% were female. All subjects had biopsy-proven disease. Thirty subjects had early-stage disease (stages I-II) and 63 had advanced disease (stages III-IV). Patients with benign pancreatic diseases included chronic pancreatitis (N=12) with a mean age of 57.5 years (range 37-78) and with 50% females, whereas IPMN included individuals with main duct and side branch IPMNs (N=8) with a mean age of 68.2 years (range 50-89) and with 87.5% being females. Subjects in the healthy control group (N=11) had a mean age of 53.4 years (range, 31-83) with 54.5% females (**Supplementary Table 1**).

We employed the novel EVtrap method (Extracellular Vesicles Total Recovery And Purification) to capture EVs from plasma samples and overcome the traditional laborious techniques for EV isolation, which are not scalable for large clinical studies. As described in recent reports, EVtrap is a magnetic bead-based isolation method that enables highly efficient capture of EVs from biofluids, confirmed by multiple common EV markers[19-23]. Over 95% recovery yield can be achieved by EVTRAP with less contamination from soluble proteins, a significant improvement over current commercially available methods as well as ultracentrifugation[19,21,24].

Following EV isolation, samples were digested in-solution and analyzed by liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS) on a high-resolution mass spectrometer (Q-Exactive HF-X). The workflow for cEVs isolation and enrichment and subsequent cEV mass spectrometry analysis is illustrated in **Figure 1**.

First, to confirm that EVtrap can efficiently isolate extracellular vesicles from plasma, a test plasma sample was processed to remove platelets and other large particles and enriched for EVs using EVtrap beads (see **methods** for details). Transmission electron microscopy (TEM) analysis of the EV pellet showed cup-shaped extracellular vesicles (exosomes and microvesicles) (**Supplementary Figure 1A**), and nanoparticle tracking analysis (NTA) using ZetaView instrument (Particle Metrix) demonstrated that the isolated EVs were in the 100–200 nm diameter range, with a mean diameter of 152 nm (**Supplementary Figure 1B**). Second, to assess the technical reproducibility of the EV proteomics approach, the test plasma sample was processed in six replicates and Pearson correlation analysis revealed a very high correlation (r2 > 0.97) between replicates (**Supplementary Figure 2A, Supplementary Table 2**). These results provided the confidence to proceed with the analysis of our discovery set of plasma from 124 subjects. In this cohort, we identified 1,708 unique proteins (**Supplementary Table 3**). The number of unique EV proteins detected per 100µL of plasma sample varied from 817 to 1,128, with an average of 912 unique proteins per sample (**Supplementary Figure 2B**). We did not observe differences between non-tumor and tumor samples regarding the overall number of EV proteins identified. Within the PDAC group, we did not observe significant differences in the

average number of EV proteins detected for different disease stages. Collectively, these data

demonstrate high reproducibility of EV isolation and robust label-free MS quantification of

cEVs.

Diseases of the Pancreas Express Distinct Circulating EV Proteome Compared to Controls

Next, we aimed at identifying specific cEV proteins associated with clinical parameters with the

potential to serve as diagnostic biomarkers. We first compared the proteomics profile of

individuals with underlying pancreatic diseases (PDAC, chronic pancreatitis and IPMN) against

healthy controls. We selected EV proteins expressed in at least 50% of subjects in the disease

group with a fold change of expression ≥2 or ≤2 compared to controls and p-value ≤0.01 after

adjusting for multiple testing. A total of 207 proteins were identified that met the criteria, with

the largest number of differentially expressed markers in PDAC (176), followed by chronic

pancreatitis (55) and IPMN (3) (**Supplementary Table 4**). Principal component analysis (PCA) of

these markers showed control samples as a tight cluster segregated away from PDAC samples

but closer to IPMN and chronic pancreatitis patients (**Figure 2A**).

Circulating EV Proteome Discriminates Pancreatic Cancer from Benign Pancreatic Diseases

To further assess the potential of cEV proteins for cancer detection, we compared proteomic

profiles of cEVs between patients with PDAC with those with underlying benign diseases of the

pancreas (chronic pancreatitis and IPMN). We identified 182 differentially expressed proteins in

malignant cases (92 over-expressed and 90 with reduced expression) (**Supplementary Table 5)**.

Several of those markers had remarkable overexpression in PDAC (greater than 10-fold),

including PDCD6IP, SERPINA12, RUVBL2, among others, as shown in the volcano plot (**Figure**

2B). Unsupervised clustering showed a clear separation between PDAC and benign pancreatic

diseases. Individuals with IPMN were more closely related to controls, whereas chronic

pancreatitis cases were more related to PDAC **(Figure 2C)**. In addition, the PDAC cohort was

separated into two subgroups: the first, enriched for early-stage tumors and more closely

related to the other pancreatic diseases (chronic pancreatitis and IPMN); the second, enriched

for advanced and metastatic cases with expression profiles further apart from early-stage

cancer and pancreatic diseases (**Figure 2C**). We further noticed that some proteins such as

PDCD6IP, SERPINA12, KRT20 showed statistically significant population-wise enrichment in

pancreatic cancer compared to benign pancreatic diseases (**Figure 2D**). Together, these data

indicate the existence of a set of EV markers that can separate controls, benign and malignant

pancreatic diseases, as well as proteins that separate early versus late-stage PDAC, suggesting

their potential to serve as diagnostic biomarkers.

Functional and Systems Biology of cEV Proteome

To gain molecular insight into the functions of the previously identified 182 proteins

differentially expressed in pancreatic cancer as compared to benign pancreatic diseases, we

conducted pathway analysis using the Gene Ontology (GO) and REACTOME databases

(**Supplementary Table 5**). We identified protein modules in protein localization, biomolecule

binding/docking, peptidase activities among changes enriched in PDAC compared to benign

diseases (**Supplementary Figure 3**). Interestingly, KRT20 (keratin 20), a gastrointestinal

epithelia-associated keratin, was increased in PDAC patient EVs, while keratins associated basal

cells, KRT4, KRT15, and KRT3, were reduced. KRT20 overexpression is frequently found in

pancreatic tumor tissues and correlates with poor prognosis[25], suggesting a biological basis for

their high levels in the cEVs of PDAC patients.

Interestingly, proteins associated with immunological functions showed complex regulation

with increased representation of leukocyte mediated immunity (GO:0002443), leukocyte

degranulation (GO:0043299), myeloid leukocyte activation (GO:0002274), and decrease in Fc

receptor signaling (GO: 0038093), regulation of complement activation (GO:0030449), and

immune effector process (GO:0002252) (**Supplementary Table 5**). These data suggest that

direct profiling of cEVs from patient plasma provided unique insights into systemic changes in

immune biology during pancreatic cancer development, which is lacked in analysis restricted to

tissue or cell models.

Circulating EV Proteomics Reveal Markers Associated with Metastasis and Worse Prognosis

We then investigated whether cEV proteins can assist in the distinction of early versus late-

stage pancreatic cancer. We compared the cEV proteome profiles of individuals with metastatic

cancer to those without metastasis and identified 85 proteins differentially expressed between

the two groups (**Supplementary Table 6)**. Supervised clustering between metastatic and non-

metastatic diseases showed a clear separation with two distinct expression patterns (**Figure**

3A). The majority of non-metastatic cases represented stages 1 and 2 diseases, with a minority

representing locally advanced stage 3 disease. In particular, PSMB4, RUVBL2 and ANKAR (**Figure**

3B) EV protein levels were increased, whereas RAP2B, SERPINA12 and IGLV4-69 abundance

levels were decreased in the cEVs of patients with metastatic disease (**Figure 3C**). Together,

these findings suggest the presence of a core set of cEV proteins with the potential to

distinguish early versus metastatic pancreatic cancer.

We further analyzed whether the expression of certain cEV proteins had prognostic relevance

in our cohort. We first classified individuals with PDAC as having low or high expression of any

given markers based on each marker's first and third quartile. Survival was estimated by the

Kaplan Meier method. We identified that the cEV expression of RALB, CRP, and CD55 had a

significant correlation with worse survival, while PDCD6IP expression had a trend for improved

outcomes (**Figure 3D**).

Validation of cEV Markers Using Parallel Reaction Monitoring and Identification an EV Protein

Signature for Pancreatic Cancer Diagnosis

Because pancreatic cancer is extremely heterogeneous, the chance of identifying a single

biomarker with sufficient diagnostic performance is likely low. Instead, the identification of a

panel of candidate markers may have enhanced diagnostic performance.

To identify a signature that shows the most discriminatory power between 'benign diseases'

and 'PDAC,' we employed a binary classification approach using Support Vector Machines

(SVM). Classification models, built based on a large number of proteins, contain irrelevant

markers that can reduce the predictive accuracy. Hence, we implemented a consensus feature

selection method based on two algorithms: one using recursive feature elimination (RFE)

algorithm (SVM-RFE)[26] and second, RFE combined with a non-parametric Wilcox rank test

(sigFeature)[27]. The top 16 markers were selected whose classification performance can be

tested in the independent validation cohort (**Supplementary Table 7**). A summary of selection

process is shown in **Supplementary Figure 4**. The classification performance of these 16

markers, individual and in all combinations, were tested using 80% training data and evaluated

in the remaining 20% test data. The quality of training was assessed using five repetitions of 10-

fold cross-validation. The optimal kernel parameters were estimated by tuning over a wide

range of values. Receiver operating characteristic (ROC) analysis was used as the metric to

assess the performance of the classifier model. We found a set of 7-EV protein signature

comprised of RUVBL2, PDCD6IP, ATP5F1, DLD, KRT20, CCT4, and SERPINAI2, that gave 100%

accuracy when tested in the discovery cohort (**Supplementary Table 7**). Recurrence of these

putative markers in our dataset varied from 55% to 97%.

The model was further validated on an independent validation cohort whose proteome was

obtained using an alternate technology, parallel reaction monitoring (PRM) mass spectrometry.

The markers chosen for validation included 16 markers selected for SVM classification model

and an additional 9 markers to result in top 25 markers that are significantly differentially

expressed in the discovery cohort with a fold change increase in PDAC ≥ 5.5 and p-value ≤0.01

(**Methods**, **Supplementary Table 8**). The independent validation cohort consisted of 36 new

subjects (24 with PDAC, 6 with chronic pancreatitis, and 6 with IPMN) (**Supplementary Table 9**).

A total of 10 proteins, including all 7 signature proteins, showed a significant difference (p <

0.05) in patients with PDAC as compared to benign pancreatic diseases (**Figure 4A**). The

performance of individual validated markers according to the specific underlying disease in the

validation cohort is presented in **Supplementary Figure 5**. The performance of 7-EV protein

signature was further tested using SVM model, in our independent validation cohort, yielding

an 89% prediction accuracy (**Figure 4B**). As expected, we observed that no single marker

achieved sufficiently high sensitivity and specificity as the combined model for the diagnosis of

pancreatic cancer.

264   **DISCUSSION**

Extracellular vesicles hold a great promise as a source of potential biomarkers, making them

attractive candidates for liquid biopsy tests. Previously, we reported that organoid cultures of

pancreatic cancer could serve as models to discover tissue-derived EV proteins with high

specificity for PDAC, as opposed to chronic pancreatitis and other benign gastrointestinal

diseases[28]. A shortcoming of these tissue-based studies is the inability to discover markers

associated to the systemic responses to cancer. Here, we performed a large-scale,

comprehensive analysis of circulating EV proteomes directly from plasma samples of 124

patients, with subsequent validation in a separate cohort of 36 patients. To our knowledge, this

represents the largest proteomics profiling dataset of circulating EVs conducted in pancreatic

cancer to date. Using this dataset, we identified and validated new EV markers from plasma

that distinguish patients with pancreatic cancer from subjects with benign pancreatic diseases.

Furthermore, we discovered several cEV proteins associated with metastatic disease and poor

prognosis. In contrast to the prior studies of experimental cell models or tissues extracts that

were examined only against healthy subjects[14-16], we report the identification of EV proteins in

plasma of patients with pancreatic cancer compared to patients with underlying pancreatic

diseases, which is clinically relevant as many patients with pancreatic cancer have underlying

chronic inflammation and premalignant cystic lesions.

In addition, our study demonstrated the feasibility of utilizing the EVtrap method[19,20] to process

patient samples in large scale within a reasonable time frame, allowing the discovery of

hundreds of EV proteins directly from a small volume (100uL) of plasma samples. This

methodological advance can be adopted for biomarker discovery in other cancer types. Other

workflows traditionally employed for EV isolation from blood samples require laborious

techniques including lengthy ultracentrifugation steps which are unsuitable for large scale

studies[29].

In this dataset, we identified several EV proteins as significantly associated with metastasis or

survival. For instance, PSMB4 and RUVBL2 levels were increased in cEVs of patients with

metastatic PDAC. Notably, PSMB4 (proteasome subunit beta type-4), a protein of the ubiquitin-

proteasome degradation pathway, has been identified as the first proteasomal subunit with

oncogenic properties and associated to poor prognosis in several tumors including melanoma,

breast and ovarian cancers[30-33].

We also discovered RALB, CRP and CD55 expression on EVs to have a significant correlation

with poor survival, while PDCD6IP expression was associated with improved outcomes.

Interestingly, PDCD6IP (programmed cell death 6-interacting protein), was also identified as a

PDAC-enriched protein in the tissue-based proteomics studies from Le Large *et.al*[34] and

Hoshino *et.al*[18]. In line with our findings, tissue expression of PDCD6IP in liver metastasis of

pancreatic cancer has been found to also correlate with improved prognosis in patients with

PDAC in the study of Law *et.al*[35]. Collectively, these data suggest that some tissue-specific

proteins can be detected in circulating EVs and their quantifiable levels in the blood may have

the potential to serve as diagnostic or prognostic biomarkers in pancreatic cancer.

In our validation studies, all seven putative markers identified from the model were significantly

enriched in the plasma of PDAC patients. Based on the top seven markers, we derived a 7-EV

protein panel that yielded an 89% prediction accuracy for diagnosing pancreatic cancer. A

recent modeling study showed that a new diagnostic assay for PDAC would have to perform

with a minimum sensitivity of 88% and a specificity of 85% to reduce healthcare expenditure

and prolong survival[6]. Serum CA19-9, the best-established blood test for PDAC, has a pooled

sensitivity of 75.4% and a specificity of 77.6%[36]. It commonly rises late in the disease and may

be elevated in nonmalignant conditions such as biliary obstruction and pancreatitis, making it

unsuitable as a diagnostic biomarker for PDAC[37]. As such, our 7-EV protein signature with 89%

prediction accuracy serves as a proof-of-concept and has the potential to facilitate the further

development of biomarker tests for pancreatic cancer. We anticipate that for clinical use

application, an even higher diagnostic performance is needed. Future studies are warranted to

investigate if combining our validated cEV proteins with other biomarkers such as cell free DNA,

serum proteins or metabolites, as a multi-analyte biomarker assay, would yield higher accuracy

in diagnosing pancreatic cancer.

While our work involved a large cohort with 160 patients, the single-center nature is an

inherent limitation of our study. Also, it would be ideal to perform validation with a larger

cohort of controls to achieve greater statistical power. To balance this limitation, we increased

the rigor of our validation by selecting controls with underlying benign diseases of pancreas as

opposed to healthy volunteers. Thus, the performance of our 7-EV protein PDAC panel should

be cross validated in larger and multicenter populations.

With no major treatment breakthrough for pancreatic cancer in the last decade, every effort

should be made to diagnose this deadly cancer at earlier stages and to discover new proteins

involved in tumorigenesis. Our study provides a valuable open resource to the scientific

community with a comprehensive catalog of novel proteins packaged inside circulating EVs that

may assist in the development of novel biomarkers and improve the outcomes of patients with

pancreatic cancer.

                                                    METHODS

Study Design and Patient Demographics

We conducted this study at Beth Israel Deaconess Medical Center with the approval of the

Harvard Cancer Center Institutional Review Board. All subjects provided written informed

consent. Clinical data and blood samples were prospectively collected from 2017 to 2019 from

patients with pancreatic cancer, chronic pancreatitis, intraductal papillary mucinous neoplasms

(IPMN), and age-matched controls. A total of 124 patients, including PDAC (N=93), chronic

pancreatitis of different etiologies (N=12), IPMN (N=8), and controls (N=11), were included in

the discovery cohort. PDAC diagnosis was established by histology or cytology, and staging was

performed according to the American Joint Committee on Cancer guidelines (8th Edition

2016)[38](**Supplementary Table 1**). For the independent validation cohort, a total of 36 patients

were enrolled, including PDAC (N=24), IPMN (N=6), and chronic pancreatitis (N=6)

(**Supplementary Table 9**).

Plasma Sample Collection and Processing

All blood samples were collected and processed following the same standard operating

procedure optimized for EV analysis and included the following steps: (i) whole blood was

collected into one 10ml yellow-top tube containing acid citrate dextrose; (ii) blood was mixed

by gently inverting the tube five times; (iii) vacutainer tubes were stored upright at room

temperature (RT); (iv) samples were centrifuged at 1,300g for 15 min in RT; (v) plasma was

removed from the top carefully avoiding cell pellet; (vi) repeat centrifugation of plasma at

2,500g for 15 min in RT; (vii) again, plasma was removed from the top carefully avoiding cell

pellet; (viii) third centrifugation at 2,500g for 15 min in RT, then samples were aliquoted to be

stored at -80^{0}C.

Extracellular Vesicle Isolation from Plasma

We employed EVtrap for EV isolation from plasma samples[19]. EVtrap beads were provided by

Tymora Analytical (West Lafayette, IN) as a suspension in water and were used as previously

described in more details[19,20]. Briefly, 100 µL plasma samples were diluted 20 times in the

diluent buffer, the EVtrap beads were added to the samples in a 1:2 v/v ratio, and the samples

were incubated by end-over-end rotation for 30 min according to the manufacturer's

instructions. After supernatant removal using a magnetic separator rack, the beads were

washed with PBS, and the EVs were eluted by a 10 min incubation with 200 mM triethylamine

(TEA, Millipore-Sigma). The samples were fully dried in a vacuum centrifuge.

Preparation of EV samples

The isolated and dried EV samples were lysed to extract proteins using the phase-transfer

surfactant (PTS) aided procedure. The proteins were reduced and alkylated by incubation in 10

mM TCEP and 40 mM CAA for 10 min at 95°C. The samples were diluted fivefold with 50 mM

triethylammonium bicarbonate and digested with Lys-C (Wako) at 1:100 (wt/wt) enzyme-to-

protein ratio for 3 h at 37°C. Trypsin was added to a final 1:50 (wt/wt) enzyme-to-protein ratio

for overnight digestion at 37°C. To remove the PTS surfactants from the samples, the samples

were acidified with trifluoroacetic acid (TFA) to a final concentration of 1% TFA, and ethyl

acetate solution was added at a 1:1 ratio. The mixture was vortexed for 2 min and then

centrifuged at 16,000 × g for 2 min to obtain aqueous and organic phases. The organic phase

(top layer) was removed, and the aqueous phase was collected. This step was repeated once

more. The samples were dried in a vacuum centrifuge and desalted using Top-Tip C18 tips

(Glygen) according to the manufacturer's instructions. The samples were dried completely in a

vacuum centrifuge and stored at -80°C.

LC–MS Analysis of Plasma EV Proteome

Approximate 1 µg of each dried peptide sample was dissolved in 10.5 µL of 0.05%

trifluoroacetic acid with 3% (vol/vol) acetonitrile containing spiked-in indexed Retention Time

Standard containing 11 artificially synthetic peptides (Biognosys). The spiked-in 11-peptides

standard mixture was used to account for any variation in retention times and to normalize

abundance levels among samples. 10 µL of each sample was injected into an Ultimate 3000

nano UHPLC system (Thermo Fisher Scientific). Peptides were captured on a 2-cm Acclaim

PepMap trap column and separated on a heated 50-cm Acclaim PepMap column (Thermo

Fisher Scientific) containing C18 resin. The mobile phase buffer consisted of 0.1% formic acid in

ultrapure water (buffer A) with an eluting buffer of 0.1% formic acid in 80% (vol/vol)

acetonitrile (buffer B) run with a linear 60-min gradient of 6–30% buffer B at a flow rate of 300

nL/min. The UHPLC was coupled online with a Q-Exactive HF-X mass spectrometer (Thermo

Fisher Scientific). The mass spectrometer was operated in the data-dependent mode, in which a

full-scan MS (from m/z 375 to 1,500 with the resolution of 60,000) was followed by MS/MS of

the 15 most intense ions (30,000 resolution; normalized collision energy - 28%; automatic gain

control target (AGC) - 2E4, maximum injection time - 200 ms; 60sec exclusion).

EV Proteome Data Processing

The raw files were searched directly against the human Swiss-Prot database with no redundant

entries using Byonic (Protein Metrics) and Sequest search engines loaded into Proteome

Discoverer 2.3 software (Thermo Fisher Scientific). MS1 precursor mass tolerance was set at 10

ppm, and MS2 tolerance was set at 20ppm. Search criteria included a static

carbamidomethylation of cysteines (+57.0214 Da) and variable modifications of oxidation

(+15.9949 Da) on methionine residues and acetylation (+42.011 Da) at the N terminus of

proteins. The search was performed with full trypsin/P digestion and allowed a maximum of

two missed cleavages on the peptides analyzed from the sequence database. The false-

discovery rates of proteins and peptides were set at 0.01. All protein and peptide identifications

were grouped, and any redundant entries were removed. Only unique peptides and unique

master proteins were reported.

All data were quantified using the label-free quantitation node of Precursor Ions Quantifier

through the Proteome Discoverer v2.3 (Thermo Fisher Scientific). For the quantification of

proteomic data, the intensities of peptides were extracted with initial precursor mass tolerance

set at 10 ppm, a minimum number of isotope peaks as 2, maximum ΔRT of isotope pattern

multiplets – 0.2 min, PSM confidence FDR of 0.01, with hypothesis test of ANOVA, maximum RT

shift of 5 min, pairwise ratio-based ratio calculation, and 100 as the maximum allowed fold

change. The abundance levels of all peptides and proteins were normalized to the spiked-in

internal iRT standard. For calculations of fold-change between the groups of proteins, total

protein abundance values were added together, and the ratios of these sums were used to

compare proteins within different samples.

The abundances of EV proteins were normalized using indexed retention time (iRT) in Proteome

Discoverer (ThermoFisher Scientific). Abundances were categorized into four different

categories: Control, Chronic Pancreatitis, IPMN, and PDAC. Protein abundances were then log2

transformed and quantile normalized for further analysis.

A non-parametric Wilcox Rank Sum test was performed to test the null hypothesis that the

distributions of two groups of the patient population are the same, and the fold change and p-

values for each protein were estimated for the following comparisons: IPMN vs. Control, CP vs.

Control, PDAC vs. Control, Benign Pancreatic Diseases (CP, IPMN) vs. PDAC. Multiple testing

correction was done using Benjamini-Hochberg method to control for the false discovery rate[39].

Volcano plots were created using those p values and fold change. Heatmaps visualization and

clustering of statistically significant proteins, with adjusted p-value ≤ 0.05 and absolute fold

change ≥ 2, were created in R using the pheatmap package. Euclidean distance and average

cluster method were used. The values were row-scaled for normalization. Both rows and

columns were allowed to cluster.

Pathways Enrichment and Protein Network Analysis

Pathway enrichment analysis was performed on statistically significant genes using g:Profiler[40],

a web-based tool that searches for pathways whose genes are significantly enriched in our

dataset compared to a collection of genes representing Gene Ontology (GO) terms and

Reactome pathways. We further used EnrichmentMap[41], a Cytoscape, v3.8.2[42] application to

create a visual network of connected pathways that helps to identify relevant pathways and

theme[43]. A Protein-Protein interaction network was generated using a stringApp, a Cytoscape

app. This application allows to import STRING networks into Cytoscape and enables to perform

complex network analysis and visualization of networks[44].

Parallel Reaction Monitoring and Data Analysis

Parallel reaction monitoring mass spectrometry (PRM-MS) was employed for validation

experiments. Twenty-five cEV markers were selected for validation based on fold change

increase ≥5.5, p-value ≤0.01, and technical aspects (number of unique peptides and coverage)

(**Supplementary Table 8**). Thirty-six plasma samples from a new cohort were used for the

validation (24 PDAC, 6 IPMN and 6 chronic pancreatitis samples). The EVs were isolated from

plasma and the proteins processed as described before. Peptide samples were dissolved in 10.8

μL 0.05% TFA & 2% ACN, and 10 μL injected into the UHPLC coupled with a Q-Exactive HF-X

mass spectrometer (Thermo Fisher Scientific). The mobile phase buffer consisted of 0.1% formic

acid in HPLC grade water (buffer A) with an eluting buffer containing 0.1% formic acid in 80%

(vol/vol) acetonitrile (buffer B) run with a linear 60-min gradient of 5–35% buffer B at a flow

rate of 300 nL/min. Each sample was analyzed under PRM with an isolation width of ±0.8 Th. In

these PRM experiments, an MS2 level at 30,000 resolution relative to m/z 200 (AGC target 2E5,

200 ms maximum injection time) was run as triggered by a scheduled inclusion list. Higher-

energy collisional dissociation was used with 28 eV normalized collision energy. PRM data were

manually curated within Skyline-daily (64-bit) 20.2.1.404 (32d27b598)[45].

Identification of EV signature for pancreatic cancer diagnosis

All algorithms for identifying the EV signature predictive of pancreatic cancer diagnosis were

implemented in R. We used Support Vector Machine (SVM) using CRAN package, e107[46].

Ranking of genes was achieved using packages 'sigFeature' and 'SVM-RFE'. An R package,

'pROC'[47] was used to build a receiver operating characteristic curve (ROC) and to calculate the

area under the curve (AUC).

Survival Analysis

The prognostic value of every protein was estimated by dividing patients into two groups:

group 1, patients with expression below the 25th percentile, and group 2, patients with

expression values greater than 75th percentile. The Kaplan-Meier estimator was used to

estimate the survival function associating survival with EV protein expression, and the log-rank

test was used to compare survival curves of two groups. 'survival' R package was used for the

analysis.

Statistical Analysis

All statistical analyses were performed using the statistical software R. Statistical significance

was calculated by two-tailed Student's t-test or Wilcoxon rank-sum test unless specified

otherwise in the figure legend. Data are expressed as mean ± SEM. A p-value < 0.05 in biological

experiments or FDR < 0.05 after multiple comparison corrections in proteomics data analysis

was considered statistically significant.

491
492

Acknowledgments

We thank the patients and their families for their participation in this study. B.B. was supported in part through UM1 (CA186709-06). S.D.F. was supported in part through the Barbara Janson and Arthur Hilsinger Pancreatology Fellowship. Institutional startup funds and UO1 (CA224193) to S.K.M., and seed grant from Hirschberg Foundation for Pancreatic Cancer Research to L.H. We thank members of the Muthuswamy laboratory for their critical input throughout the development of this project.

Competing Interest Statement

B.B. reports Research Funding: Agenus Inc, NanoView Bioscience; Travel Expenses: Erytech Pharma; Advisory Board and Consulting: Blueprint Medicines, Bioline Rx. A.B. reports Advisory/Consulting with Exelixis and Geistlich Pharma. A.I. and W.A.T. are principals at Tymora Analytical Operations, which developed EVtrap beads. M.H. reports grants from Weill Cornell Medicine; personal fees from Agenus, BMS, Oncomatrix, Khar, Inxmed, Genchem, Cantargia, and Fibrogen outside the submitted work; patent for Method for ACT in PDAC licensed to Peaches SL; and Director of BMS. S.K.M. owns stocks and is a member of the Scientific Advisory Board of KAHR Medical. The remaining authors declare no related competing interests.

REFERENCES

514
515
516
1.   Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70:7-30,
2020
2.   Rahib L, Smith BD, Aizenberg R, et al: Projecting cancer incidence and deaths to
2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Cancer Res 74:2913-21, 2014
3.   Kamisawa T, Wood LD, Itoi T, et al: Pancreatic cancer. Lancet 388:73-85, 2016
4.   Rahib L, Fleshman JM, Matrisian LM, et al: Evaluation of Pancreatic Cancer
Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.
JAMA Oncol 2:1209-16, 2016
5.   Bockorny B, Grossman JE, Hidalgo M: Facts and Hopes in Immunotherapy of
Pancreatic Cancer. Clin Cancer Res 28:4606-4617, 2022
6.   Ghatnekar O, Andersson R, Svensson M, et al: Modelling the benefits of early
diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer 133:2392-7, 2013
7.   Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic Cancer Registry in Japan: 20
years of experience. Pancreas 28:219-30, 2004
8.   Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for
the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-27, 2006
9.   Galli C, Basso D, Plebani M: CA 19-9: handle with care. Clin Chem Lab Med
51:1369-83, 2013
10.   Chen IH, Xue L, Hsu CC, et al: Phosphoproteins in extracellular vesicles as
candidate markers for breast cancer. Proc Natl Acad Sci U S A 114:3175-3180, 2017
11.   Costa-Silva B, Aiello NM, Ocean AJ, et al: Pancreatic cancer exosomes initiate
pre-metastatic niche formation in the liver. Nat Cell Biol 17:816-26, 2015
12.   van Niel G, Carter DRF, Clayton A, et al: Challenges and directions in studying
cell-cell communication by extracellular vesicles. Nat Rev Mol Cell Biol 23:369-382, 2022
13.   Melo SA, Luecke LB, Kahlert C, et al: Glypican-1 identifies cancer exosomes and
detects early pancreatic cancer. Nature 523:177-82, 2015
14.   Madhavan B, Yue S, Galli U, et al: Combined evaluation of a panel of protein and
miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and
specificity. Int J Cancer 136:2616-27, 2015
15.   Yang KS, Im H, Hong S, et al: Multiparametric plasma EV profiling facilitates
diagnosis of pancreatic malignancy. Sci Transl Med 9, 2017
16.   Castillo J, Bernard V, San Lucas FA, et al: Surfaceome profiling enables isolation
of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol
29:223-229, 2018
17.   Fahrmann JF, Mao X, Irajizad E, et al: Plasma-Derived Extracellular Vesicles
Convey Protein Signatures that Reflect Pathophysiology in Lung and Pancreatic
Adenocarcinomas. Cancers (Basel) 12, 2020
18.   Hoshino A, Kim HS, Bojmar L, et al: Extracellular Vesicle and Particle Biomarkers
Define Multiple Human Cancers. Cell 182:1044-1061 e18, 2020

19.   Iliuk A, Wu X, Li L, et al: Plasma-Derived Extracellular Vesicle Phosphoproteomics
through Chemical Affinity Purification. J Proteome Res 19:2563-2574, 2020
20.   Wu X, Li L, Iliuk A, et al: Highly Efficient Phosphoproteome Capture and Analysis
from Urinary Extracellular Vesicles. J Proteome Res 17:3308-3316, 2018
21.   Nunez Lopez YO, Iliuk A, Petrilli AM, et al: Proteomics and Phosphoproteomics of
Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology. Int J Mol Sci
23, 2022
22.   Hinzman CP, Jayatilake M, Bansal S, et al: An optimized method for the isolation
of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for
radiation exposure. J Transl Med 20:199, 2022
23.   Hinzman CP, Singh B, Bansal S, et al: A multi-omics approach identifies pancreatic
cancer cell extracellular vesicles as mediators of the unfolded protein response in normal
pancreatic epithelial cells. J Extracell Vesicles 11:e12232, 2022
24.   Shuen TWH, Alunni-Fabbroni M, Ocal E, et al: Extracellular Vesicles May Predict
Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular
Carcinoma: An Exploratory Analysis from the SORAMIC Trial. Clin Cancer Res 28:3890-3901,
2022
25.   Schmitz-Winnenthal FH, Volk C, Helmke B, et al: Expression of cytokeratin-20 in
pancreatic cancer: an indicator of poor outcome after R0 resection. Surgery 139:104-8, 2006
26.   Guyon I, Weston J, Barnhill S, et al: Gene Selection for Cancer Classification using
Support Vector Machines. Machine Learning 46:389-422, 2002
27.   Das P, Roychowdhury A, Das S, et al: sigFeature: Novel Significant Feature
Selection Method for Classification of Gene Expression Data Using Support Vector Machine and
t Statistic. Front Genet 11:247, 2020
28.   Huang L, Bockorny B, Paul I, et al: PDX-derived organoids model in vivo drug
response and secrete biomarkers. JCI Insight, 2020
29.   LeBleu VS, Kalluri R: Exosomes as a Multicomponent Biomarker Platform in
Cancer. Trends Cancer 6:767-774, 2020
30.   Liu R, Lu S, Deng Y, et al: PSMB4 expression associates with epithelial ovarian
cancer growth and poor prognosis. Arch Gynecol Obstet 293:1297-307, 2016
31.   Zhang X, Lin D, Lin Y, et al: Proteasome beta-4 subunit contributes to the
development of melanoma and is regulated by miR-148b. Tumour Biol 39:1010428317705767,
2017
32.   Zheng P, Guo H, Li G, et al: PSMB4 promotes multiple myeloma cell growth by
activating NF-kappaB-miR-21 signaling. Biochem Biophys Res Commun 458:328-33, 2015
33.   Lee GY, Haverty PM, Li L, et al: Comparative oncogenomics identifies PSMB4 and
SHMT2 as potential cancer driver genes. Cancer Res 74:3114-26, 2014
34.   Le Large TY, Mantini G, Meijer LL, et al: Microdissected pancreatic cancer
proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight 5, 2020
35.   Law HC, Lagundzin D, Clement EJ, et al: The Proteomic Landscape of Pancreatic
Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with
Clinical Response. Clin Cancer Res 26:1065-1076, 2020
36.   Zhang Y, Yang J, Li H, et al: Tumor markers CA19-9, CA242 and CEA in the
diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med 8:11683-91, 2015

601   37. Duffy MJ, Sturgeon C, Lamerz R, et al: Tumor markers in pancreatic cancer: a
602 European Group on Tumor Markers (EGTM) status report. Ann Oncol 21:441-7, 2010
603   38. Amin MB, Greene FL, Edge SB, et al: The Eighth Edition AJCC Cancer Staging
604 Manual: Continuing to build a bridge from a population-based to a more "personalized"
605 approach to cancer staging. CA Cancer J Clin 67:93-99, 2017
606   39. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and
607 Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B
608 (Methodological) 57:289-300, 1995
609   40. Raudvere U, Kolberg L, Kuzmin I, et al: g:Profiler: a web server for functional
610 enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res 47:W191-
611 W198, 2019
612   41. Merico D, Isserlin R, Stueker O, et al: Enrichment map: a network-based method
613 for gene-set enrichment visualization and interpretation. PLoS One 5:e13984, 2010
614   42. Shannon P, Markiel A, Ozier O, et al: Cytoscape: a software environment for
615 integrated models of biomolecular interaction networks. Genome Res 13:2498-504, 2003
616   43. Reimand J, Isserlin R, Voisin V, et al: Pathway enrichment analysis and
617 visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc
618 14:482-517, 2019
619   44. Szklarczyk D, Gable AL, Lyon D, et al: STRING v11: protein-protein association
620 networks with increased coverage, supporting functional discovery in genome-wide
621 experimental datasets. Nucleic Acids Res 47:D607-D613, 2019
622   45. MacLean B, Tomazela DM, Shulman N, et al: Skyline: an open source document
623 editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26:966-8,
624 2010
625   46. Meyer D, Dimitriadou E, Hornik K, et al: Misc Functions of the Department of
626 Statistics, ProbabilityTheory Group (Formerly: E1071), TU Wien, 2015
627   47. Robin X, Turck N, Hainard A, et al: pROC: an open-source package for R and S+ to
628 analyze and compare ROC curves. BMC Bioinformatics 12:77, 2011

 FIGURES

Figure 1. Study Design

The discovery cohort was comprised of 124 individuals, including pancreatic ductal

adenocarcinoma (PDAC, N=93), chronic pancreatitis (CP, N=12), intraductal papillary mucinous

neoplasm (IPMN, N=8) and healthy controls (N=11). Plasma samples were processed for EV

isolation using EVtrap and analyzed by liquid chromatography-tandem mass spectrometry (LC-

MS/MS).

Figure 2. Identification of cEV Proteins Differentially Expressed in Disease Groups

(A) Principal component analysis of cEV proteins differentially expressed in the plasma of

patients with pancreatic diseases compared to controls. Each dot indicates one individual

enrolled in the study: green, controls; blue, patients with intraductal papillary mucinous

neoplasm (IPMN); purple, patients with chronic pancreatitis (CP); salmon, early stage (stages I

and II) pancreatic ductal adenocarcinoma (PDAC); red, late stage (stages III and IV) PDAC.

(B) Volcano plot of circulating EV proteins enriched in the plasma of patients with PDAC versus

benign pancreatic diseases. X-axis, log base 2 of fold changes; Y-axis, negative of the log base 10

of p values

(C) Heatmap of cEV proteins differentially expressed in the plasma of patients with pancreatic

diseases compared to controls. Designations of clinical parameters were indicated at the top of

the heatmap.

(D) Expression of enriched cEV proteins in patients with PDAC versus benign pancreatic

diseases. Each dot indicates the target protein signal from one patient. Y-axis, normalized log

base 2 of protein signals detected by mass spectrometry; Error bars, min and max values; lines

in boxes, median values. ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$.

Figure 3. Circulating EV Proteomics Reveal Markers Associated with Metastasis and Worse

Prognosis.

(A) Heatmap showing EV proteins differentially expressed in the plasma of metastatic versus

non-metastatic PDAC. Designations of clinical parameters are indicated at the top of the

heatmap.

(B) Expression patterns of cEV proteins associated with metastatic disease. Y-axis, normalized

log base 2 of protein signals detected by mass spectrometry; N, non-metastatic PDAC group; M,

metastatic PDAC group. Each dot indicated the target protein signal from one patient. Error

bars, min and max values; lines in boxes, median values. ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq$

0.0001.

(C) As is **(B)**, except for cEV markers with increased expression in non-metastatic PDAC.

(D) Correlation of cEV marker expression with survival. Kaplan–Meier curves and log-rank test P

values of representative survival cEV markers quantified in the discovery cohort.

Figure 4. Validation of cEV Markers and Identification of 7-EV Protein Signature for PDAC

Diagnosis.

(A) Differences of cEV protein abundances between patients with PDAC (n=24) and benign

pancreatic diseases (chronic pancreatitis and IPMN) (n=12). x axis, minus log *p* values of protein

abundance differences between PDAC and benign groups; y axis, average fold changes of

proteins in PDAC group compared to benign group. Size of bubbles indicate average protein

abundances in PDAC group. Pink color, proteins that had at least two-fold enrichment in PDAC

group (p<0.05).

(B) ROC curves were calculated for individual cEV markers as well as for the 7-EV protein PDAC

signature combination to determine optimum diagnostic performance. AUC, area under the

curve.

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Baseline characteristics of patients enrolled on the discovery cohort.

Supplementary Table 2. Plasma EV analysis reproducibility

Supplementary Table 3. LC-MS results of EV analysis of plasma from patients with PDAC (PA),

IPMN, Chronic Pancreatitis (CP) and Control individuals.

Supplementary Table 4. List of EV proteins that met the eligibility criteria for principal

component analysis.

Supplementary Table 5. List of 182 proteins differentially expressed in PDAC compared to

benign diseases.

Supplementary Table 6. List of EV proteins that are significantly altered in patients with

metastatic versus non-metastatic diseases.

Supplementary Table 7. Support Vector Machine Prediction of 16 individual genes in Discovery

Test and Validation Cohorts

Supplementary Table 8. List of 25 cEV proteins that met the eligibility criteria for validation

studies.

Supplementary Table 9. Baseline characteristics of patients enrolled in the validation cohort.

Supplementary Figure 1. EVtrap isolation of extracellular vesicles

(A) Transmission electron microscopy (TEM) images collected of a single EV and multiple EVs

captured from plasma by EVtrap. TEM imaging of EVs was carried out on a HITACHI H-8100

electron microscope (Hitachi, Tokyo, Japan) with an accelerating applied potential of 200 kV.

(B) Nanoparticle tracking analysis (NTA) of EVs after elution off EVtrap beads. NTA was carried

out using ZetaView instrument (Particle Metrix) after calibration with 100 nm polystyrene

particles.

Supplementary Figure 2. EV proteomics analytical performance

(A) Reproducibility of the method. A test plasma sample was processed in six replicates and performed a Pearson correlation analysis that revealed a very high correlation between replicates.

(B) Number of quantified EV proteins per sample according to different patient cohort.

Supplementary Figure 3. **Network Analyses of cEV Proteins Differentially Expressed in PDAC Compared to Benign Pancreatic Diseases.**

(A) Functional association of proteins identified by STRING database. Red, cEV proteins enriched in PDAC patients as compared to benign pancreatic diseases. Green, cEV proteins decreased in patients with PDAC as compared to benign pancreatic diseases. Red, cEV proteins increased in PDAC as compared to benign pancreatic diseases. Thickness of lines indicate confidence of association.

(B, C) Clustering of cEV protein pathways enriched **(B)** or downregulated **(C)** in PDAC cohorts. Pathways were identified using Gene Ontology database and REACTOME database.

Supplementary Figure 4. Summary of selection process to develop EV signature for pancreatic cancer diagnosis.

Supplementary Figure 5. Validation of individual cEV proteins in an independent cohort of patients.

743   Expression of biomarker candidates detected by Parallel Reaction Monitoring (PRM) analyses. A

744   total of 25 cEV proteins with significant overexpression in PDAC in the discovery cohorts were

745   quantified by PRM in a separate validation cohort of patients.

750
751

Figure 1

Discovery Cohort
N=124

Controls

IPMN

CP

PDAC

EV Isolation

EVtrap

LC-MS/MS

EV Proteome Profile

Intensity

Figure 2

Figure 3

A

B

Figure 4

Suppl. Figure 3